Elagolix for heavy menstrual bleeding in women with uterine fibroids

WD Schlaff, RT Ackerman, A Al-Hendy… - … England Journal of …, 2020 - Mass Medical Soc
Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

[HTML][HTML] Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study

DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and sterility, 2017 - Elsevier
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …

Treatment of uterine fibroid symptoms with relugolix combination therapy

A Al-Hendy, AS Lukes, AN Poindexter III… - … England Journal of …, 2021 - Mass Medical Soc
Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …

Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial

BR Carr, EA Stewart, DF Archer, A Al-Hendy… - Obstetrics & …, 2018 - journals.lww.com
OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor
antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual …

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart, L Bradley, E Marsh… - The Lancet, 2022 - thelancet.com
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas

JA Simon, A Al-Hendy, DF Archer… - Obstetrics & …, 2020 - journals.lww.com
OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-
releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in …

Ulipristal acetate versus leuprolide acetate for uterine fibroids

J Donnez, J Tomaszewski, F Vázquez… - … England Journal of …, 2012 - Mass Medical Soc
Background The efficacy and side-effect profile of ulipristal acetate as compared with those
of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are …

[HTML][HTML] Long-term treatment of uterine fibroids with ulipristal acetate☆

J Donnez, F Vázquez, J Tomaszewski, K Nouri… - Fertility and sterility, 2014 - Elsevier
Objective To investigate the efficacy and safety of ulipristal acetate (UPA) for long-term
treatment of symptomatic uterine fibroids. Design Repeated intermittent open-label UPA …

Uterine fibroids: an update on current and emerging medical treatment options

M Farris, C Bastianelli, E Rosato, I Brosens… - … and clinical risk …, 2019 - Taylor & Francis
Uterine fibroids are the most common gynecological disorder, classically requiring surgery
when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it …

[HTML][HTML] Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo …

Y Osuga, K Enya, K Kudou, H Hoshiai - Fertility and sterility, 2019 - Elsevier
Objective To investigate the efficacy and safety of the oral gonadotropin-releasing hormone
receptor antagonist, relugolix, in patients experiencing uterine fibroid–associated pain …